A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

Phase 2 Completed 183 enrolled Unity Biotechnology, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).

Timeline

Start: 2019-10-30
Primary completion: 2020-05-20
Completion: 2020-08-07

Publications

Hannani MT, Frederiksen P, Karsdal MA, Bager CL, Bihlet AR, Tunblad K, Oberg F, Collins JE, Kraus VB, Hunter DJ, Bacardit J, Bay-Jensen AC, Thudium CS. Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials. Arthritis Res Ther. 2026 May 7;28(1):133. doi: 10.1186/s13075-026-03825-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UBX0101	Unknown	0.5 mg	Other
Subject	UBX0101	Unknown	2 mg	Other
Subject	UBX0101	Unknown	4 mg	Other

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

Summary

Timeline

Publications

Drugs

Indications